What Would US FDA Do If Supreme Court Eliminates Or Curtails Chevron Deference?
Lawyers say agency will have to bolster its administrative record as judges tackle complex policy and scientific issues previously left to FDA. Some cases, such as challenges to exclusivity decisions, may be reopened.
You may also be interested in...
Ruling upheld Massachusetts federal court’s approval of Vitamin Shoppe’s motion for summary judgement. Complaint alleged because the firm “substantiated its claims about supplemental glutamine with evidence about naturally occurring glutamine, the claims are not substantiated” under FDA’s structure/function claim rule and FDCA doesn’t preempt state law claims.
West Virginia judge finds GenBioPro has standing to sue state and that Comstock Act does not prohibit mailing of medication abortion drugs. Ruling deepens conflict between courts as Fifth Circuit hears appeal of Texas district court order staying approval of mifepristone.
Supreme Court nominee issued three decisions on Hatch-Waxman regime as district court judge, including case in which she ruled against the FDA’s denial of orphan drug designation and another in which she deferred to the agency’s view on exclusivity. Her analysis of facts may play a role if the court takes up a case on administrative agency deference.